Vosevi Application Scope

Vosevi is a prescription medication used to treat chronic hepatitis C in adults, especially for those who have previously been treated with other antiviral medicines without success.

vosevi

Characteristics

Ingredients: Sofosbuvir, Velpatasvir and Voxilaprevir

Properties:
- Sofosbuvir: NS5B RNA polymerase inhibitor
- Velpatasvir: NS5A inhibitor
- Voxilaprevir: NS3/4A protease inhibitor
Packaging Specification:
- High-density polyethylene (HDPE) bottle with a polypropylene child-resistant closure
- Containing 28 film-coated tablets, along with a silica gel desiccant
Storage:
- Store below 30°C (86°F)
- Keep in the original container with the desiccant to protect from moisture
- Keep the bottle tightly closed
Expiry Date: Shelf life is 4 years from the date of manufacture
Executive Standard: Approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA)
Approval Number: U.S. FDA approval granted in July 2017
Date of Revision: Last revised in 2023
Manufacturer: Gilead Sciences Ireland UC, Carrigtohill, County Cork, T45 DP77, Ireland

Guidelines for the Use of Vosevi

Dosage and Administration:
- Recommended dosage: One tablet taken orally once daily with food
- Treatment duration: 12 weeks for patients without cirrhosis or with compensated cirrhosis (Child-Pugh A)
Adverse Reactions:
Common side effects include:
- Headache
- Fatigue
- Diarrhea
- Nausea
Contraindications: Co-administration with rifampin is contraindicated
Precautions:
- Risk of hepatitis B virus (HBV) reactivation in patients co-infected with HCV and HBV
- Serious symptomatic bradycardia when co-administered with amiodarone
- Use with caution in patients with moderate or severe hepatic impairment (Child-Pugh B or C)

Vosevi Interactions

Drug Interactions:
- Avoid co-administration with:
  - Phenytoin
  - Phenobarbital
  - Oxcarbazepine
  - Rifabutin
  - Rifapentine
  - Atazanavir
  - Lopinavir
  - Tipranavir/ritonavir
  - Efavirenz
  - Rosuvastatin
  - Pitavastatin
  - Cyclosporine
- St. John’s Wort may reduce serum levels of voxilaprevir; avoid concurrent use
- Antacids may reduce the serum levels of velpatasvir; administer Vosevi at least 4 hours before or after antacids

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.